Literature DB >> 31338558

Histopathology-based immunoscore predicts recurrence for intrahepatic cholangiocarcinoma after hepatectomy.

Meng-Xin Tian1,2, Yu-Fu Zhou1,2, Wei-Feng Qu1,2, Wei-Ren Liu1,2, Lei Jin1,2, Xi-Fei Jiang1,2, Han Wang1,2, Chen-Yang Tao1,2, Pei-Yun Zhou1,2, Yuan Fang1,2, Zhen-Bin Ding1,2, Yuan-Fei Peng1,2, Jian Zhou1,2,3, Jia Fan1,2,3, Ying-Hong Shi4,5.   

Abstract

Intrahepatic cholangiocarcinoma (ICC) is a rare malignancy with poor prognosis. The evaluation of recurrence risk after liver resection is of great importance for ICCs. We aimed to assess the prognostic value of intra- and peritumoral immune infiltrations and to establish a novel histopathology-related immunoscore (HRI) associated with ICC recurrence. A total of 280 ICC patients who received curative resection between February 2005 and July 2011 were enrolled in our study. Patients were randomly assigned to the derivation cohort (n = 176) or the validation cohort (n = 104). Sixteen immune biomarkers in both intra- and peritumoral tissues were examined by immunohistochemistry. The least absolute shrinkage and selection operator (LASSO) Cox model was used to establish the HRI score. Cox regression analysis was used for multivariate analysis. Nine recurrence-related immune features were identified and integrated into the HRI score. The HRI score was used to categorize patients into low-risk and high-risk groups using the X-tile software. Kaplan-Meier analysis presented that the HRI score showed good stratification between low-risk and high-risk groups in both the derivation cohort (P < 0.001) and the validation cohort (P = 0.014), respectively. Multivariate analysis demonstrated that serum γ-glutamyl transpeptidase, carbohydrate antigen 19-9, lymphoid metastasis, tumor numbers, and the HRI score were independent risk factors associated with recurrence-free survival (RFS). The combination of Shen's model and HRI score provided better performance in recurrence prediction compared with traditional staging systems. The HRI score might serve as a promising RFS predictor for ICC with prognostic values.

Entities:  

Keywords:  Immunoscore; Intrahepatic cholangiocarcinoma; Prognosis; Recurrence

Mesh:

Substances:

Year:  2019        PMID: 31338558     DOI: 10.1007/s00262-019-02371-3

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  6 in total

1.  Adjuvant chemotherapy for intrahepatic cholangiocarcinoma: far from a clinical consensus.

Authors:  Wei-Feng Qu; Wei-Ren Liu; Ying-Hong Shi
Journal:  Hepatobiliary Surg Nutr       Date:  2021-12       Impact factor: 7.293

2.  Immunoscore is a strong predictor of survival in the prognosis of stage II/III gastric cancer patients following 5-FU-based adjuvant chemotherapy.

Authors:  Sumi Yun; Jiwon Koh; Soo Kyung Nam; Yoonjin Kwak; Sang-Hoon Ahn; Joong Do Park; Hyung-Ho Kim; Woo Ho Kim; Hye Seung Lee
Journal:  Cancer Immunol Immunother       Date:  2020-08-12       Impact factor: 6.968

3.  Integrating Machine Learning and Tumor Immune Signature to Predict Oncologic Outcomes in Resected Biliary Tract Cancer.

Authors:  Gu-Wei Ji; Ke Wang; Yong-Xiang Xia; Jin-Song Wang; Xue-Hao Wang; Xiang-Cheng Li
Journal:  Ann Surg Oncol       Date:  2020-11-23       Impact factor: 5.344

Review 4.  Intrahepatic cholangiocarcinoma: Morpho-molecular pathology, tumor reactive microenvironment, and malignant progression.

Authors:  Alphonse E Sirica; Mario Strazzabosco; Massimiliano Cadamuro
Journal:  Adv Cancer Res       Date:  2020-12-09       Impact factor: 6.242

5.  Age-adjusted Charlson Comorbidity Index predicts survival in intrahepatic cholangiocarcinoma patients after curative resection.

Authors:  Wei-Feng Qu; Pei-Yun Zhou; Wei-Ren Liu; Meng-Xin Tian; Lei Jin; Xi-Fei Jiang; Han Wang; Chen-Yang Tao; Yuan Fang; Yu-Fu Zhou; Shu-Shu Song; Zhen-Bin Ding; Yuan-Fei Peng; Zhi Dai; Shuang-Jian Qiu; Jian Zhou; Jia Fan; Zheng Tang; Ying-Hong Shi
Journal:  Ann Transl Med       Date:  2020-04

6.  Percutaneous isolated hepatic perfusion (chemosaturation) with melphalan following right hemihepatectomy in patients with cholangiocarcinoma and metastatic uveal melanoma: peri- and post-interventional adverse events and therapy response compared to a matched group without prior liver surgery.

Authors:  C L A Dewald; L S Becker; S K Maschke; T C Meine; T A Alten; M M Kirstein; A Vogel; F K Wacker; B C Meyer; J B Hinrichs
Journal:  Clin Exp Metastasis       Date:  2020-10-09       Impact factor: 5.150

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.